首页> 外国专利> 8- (3-Aminopiperidin-1-yl) -7-but-2-inyl-3-methyl-1- (4-methylchinazolin-2-ylmethyl) -3,7-dihydropurin-2,6-dion, the enantiomers and their salts, in particular Linagliptin * combined with metformin hydrochloride. * Linagliptin = ((R) -8- (3-Aminopiperidin-1-yl) -7-but-2-inyl-3-methyl-1 (4-methylchinazolin-2-ylmethyl) -3,7-dihydropurin-2,6-dion) (IUPAC)

8- (3-Aminopiperidin-1-yl) -7-but-2-inyl-3-methyl-1- (4-methylchinazolin-2-ylmethyl) -3,7-dihydropurin-2,6-dion, the enantiomers and their salts, in particular Linagliptin * combined with metformin hydrochloride. * Linagliptin = ((R) -8- (3-Aminopiperidin-1-yl) -7-but-2-inyl-3-methyl-1 (4-methylchinazolin-2-ylmethyl) -3,7-dihydropurin-2,6-dion) (IUPAC)

机译:8-(3-氨基哌啶-1-基)-7-but-2-in-3--3-甲基-1-(4-甲基中国唑啉-2-基甲基)-3,7-二氢嘌呤-2,6-dion,对映异构体及其盐类,特别是利拉列汀*与盐酸二甲双胍合用。 *利格列汀=((R)-8-(3-氨基哌啶-1-基)-7-but-2-inyl-3-methyl-1(4-methylchinazolin-2-ylmethyl)-3,7-dihydropurin-2 ,6-dion)(IUPAC)

摘要

8-(3-amino-piperidin-1-yl)-xanthine derivatives (I) are new. 8-(3-amino-piperidin-1-yl)-xanthine derivatives of formula (I) and their tautomers, enantiomers, diastereomers (or mixtures), prodrugs and salts are new. [Image] R 1 : CH 2Q 1, CH 2CH 2OMe, CH 2CH 2OPh, CH 2CH 2CN, CH 2COPh or CHMeCOPh, phenylcarbonylmethyl mono-substituted in the ring by Q 2 or phenylcarbonylmethyl substituted in the ring by two OMe groups or on two adjacent C-atoms by OCH 2O, OCH 2CH 2O or N(Me)COO; Q 1 : CONMe 2, heterocycle or heteroaryl (optionally substituted); Q 2 : NH 2, NHCH 2CN, NHCOMe, NHCOEt, NHCOCHMe 2, NHCOOMe, NHCONHCOOEt, 2-oxo-imidazolin-1-yl, COOH, COMe, COOEt, CONH 2, CONHMe, CONMe 2, morpholinocarbonyl, SMe, SOMe, SO 2Me, OCH 2COOH, OCH 2COOEt, OCH 2COOCHMe 2, OCH 2CONH 2, OCH 2CONHMe, OCH 2CONHEt, OCH 2CONHCHMe 2, OCH 2CONMe 2, pyrrolidinocarbonyl-methoxy, morpholinocarbonyl-methoxy, OCHMeCOOEt, OCHMeCONH 2 or OCH 2SOMe; R 2 : Me, CHMe 2 or Ph, and R 3 : CH 2C(Me)=CH 2, CH 2C(Cl)=CH 2, CH 2CH=CHBr, CH 2CH=CHMe, CH 2C(Me)=CMe 2, CH 2CCMe, 1-cyclopenten-1-ylmethyl or 2-furanylmethyl. An independent claim is included for the preparation of (I). ACTIVITY : Antidiabetic; Antiarthritic; Anorectic; Immunosuppressive; Osteopathic; Ophthalmological; Nephrotropic; Neuroprotective; Antiarteriosclerosis; Tranquilizer; Cardiant; Diuretic; Hypotensive; Antiinflammatory; Antiulcer; Antiinfertility; Antirheumatic; Antithyroid; Virucide; Anti-HIV; Cytostatic; Nootropic; Cerebroprotective; Antiparkinsonian; Antimigraine; Antianemic; Dermatological; Antipsoriatic; Antidepressant. MECHANISM OF ACTION : Dipeptidylpeptidase-IV (DPP-IV) inhibitor; B-cell degeneration inhibitor; glucagon-like peptide (GLP) action modulator. 1-((Quinazolin-2-yl)-methyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (Ia) had an IC 50 value of 1 nM for inhibition of DPP-IV.
机译:8-(3-氨基-哌啶-1-基)-黄嘌呤衍生物(I)是新的。式(I)的8-(3-氨基-哌啶-1-基)-黄嘌呤衍生物及其互变异构体,对映异构体,非对映异构体(或混合物),前药和盐是新的。 [图像] R 1>:CH 2Q 1>,CH 2CH 2OMe,CH 2CH 2OPh,CH 2CH 2CN,CH 2COPh或CHMeCOPh,在环中被Q 2>单取代的苯羰甲基或在环中被两个OMe基取代的苯羰甲基OCH 2O,OCH 2CH 2O或N(Me)COO在两个相邻的C原子上; Q 1>:CONMe 2,杂环或杂芳基(任选取代的); Q 2>:NH 2,NHCH 2CN,NHCOMe,NHCOEt,NHCOCHMe 2,NHCOOMe,NHCONHCOOEt,2-氧代-咪唑啉-1-基,COOH,COMe,COOEt,CONH 2,CONHMe,CONMe 2,吗啉代羰基,SMe,SOMe ,SO 2Me,OCH 2COOH,OCH 2COOEt,OCH 2COOCHMe 2,OCH 2CONH 2,OCH 2CONHMe,OCH 2CONHEt,OCH 2CONHCHMe 2,OCH 2CONMe 2,吡咯烷基羰基甲氧基,吗啉代羰基甲氧基,OCHMeCOOEt,OCHMeCONH 2或OCH 2SOMe R 2>:Me,CHMe 2或Ph,并且R 3>:CH 2C(Me)= CH 2,CH 2C(Cl)= CH 2,CH 2CH = CHBr,CH 2CH = CHMe,CH 2C(Me)= CMe 2,CH 2CCMe,1-环戊烯-1-基甲基或2-呋喃基甲基。包括独立权利要求用于制备(I)。活动:抗糖尿病;抗关节炎厌食的;免疫抑制整骨;眼科嗜肾具有神经保护作用;抗动脉硬化;镇静剂;卡迪恩利尿剂降压;消炎(药;抗溃疡;抗不孕症;抗风湿;抗甲状腺;杀病毒剂;抗艾滋病毒;细胞抑制促智;脑保护反帕金森病;抗偏头痛;抗贫血;皮肤;对牛皮癣;抗抑郁药。作用机理:二肽基肽酶-IV(DPP-IV)抑制剂; B细胞变性抑制剂;胰高血糖素样肽(GLP)作用调节剂。 1-((喹唑啉-2-基)-甲基)-3-甲基-7-(2-丁炔-1-基)-8-((R)-3-氨基哌啶-1-基)-黄嘌呤( Ia)对于DPP-IV的抑制具有IC 50值为1nM。

著录项

  • 公开/公告号LU92128I2

    专利类型

  • 公开/公告日2013-03-11

    原文格式PDF

  • 申请/专利权人 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG;

    申请/专利号LU20130092128C

  • 发明设计人

    申请日2013-01-09

  • 分类号A61K9/02;A61K9/20;A61K9/28;A61K9/48;A61K47/02;A61P3/10;C07D473/04;C07D473/06;C07D473/08;

  • 国家 LU

  • 入库时间 2022-08-21 16:40:56

获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号